Cara's PhII analgesic reducing morphine use in acute post-operative pain
This article was originally published in Scrip
Executive Summary
The US venture Cara Therapeutics has reported that its novel, peptide-based peripherally-acting kappa opioid agonist, CR845, met its goals in a Phase II placebo-controlled trial when administered as an iv formulation both pre- and post-operatively for acute post-operative pain in women undergoing laparoscopic hysterectomy.